drugset / Trial / NCT02221648

Investigation of Efficacy of Botulinum Toxin A (Dysport) in Chronic Low Back Pain

NCT02221648

Phase 2 Terminated 43 enrolled Yale University Ipsen · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

The scientific aim of this study is to investigate the efficacy of abobotulinumtoxinA (Dysport - Ipsen Pharmaceuticals) in chronic low back pain. The investigators hypothesis is that injection of Dysport brand of botulinum toxin type A into erector spinae muscles (extensors of the spine) can relieve low back pain through anti-spasm and analgesic effect of botulinum toxin.

Timeline

Start
2012-12
Primary completion
2015-09
Completion
2015-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Botulinum toxin type A Protein / enzyme biologic 500 iu Intramuscular
Comparator Botulinum toxin type A Protein / enzyme biologic 1000 iu Intramuscular

Indications

No indication recorded.